8. Method according to any one of claims 5 to 7, characterized in that the tracer antibody is conjugated to digoxygenin and linking to the detectable label is performed via an antibody against digoxygenin.

9. The method according to any one of claims 4 to 8, characterized in that said human or humanized antibody is a Fab.

10. Use of an antibody which is binding to a human or humanized antibody and not binding to the immunoglobulin of an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgus for measuring the concentration of total, active, or antigen-bound human or humanized antibody in a sample obtained from an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgus whereby the antibody is an antibody according to claim 2.

11. Antibody composition, characterized in comprising a mixture of antibodies produced by the cell line DSM ACC3006, the cell line DSM ACC3007, and the cell line DSM ACC3008.

12. Use of an antibody composition according to claim 11 in a method according to any one of claims 4 to 9.

13. Antibody binding to human or chimpanzee IgG and not binding to canine and marmoset IgG, characterized in that the K_D-value for binding to a human or chimpanzee IgG is 10^{-9} mol/l or less and characterized in that the antibody is obtained from one of the cell lines DSM ACC3006, DSM ACC3007, or DSM ACC3008.

14. The antibody according to claim 13, characterized in that the antibody is not binding to canine, Rhesus-monkey, marmoset, baboon, and cynomolgus IgG, characterized in that the K_D-value for binding to canine, Rhesus-monkey, marmoset, baboon, and cynomolgus IgG is 10^{-6} mol/l or more.

15. The antibody according to any one of claims ~~16~~ 13 ~~to~~ or ~~18~~14, characterized in that the antibody is a monoclonal antibody.

16. Use of an antibody according to any one of claims 13 to 15 in a method according to any one of claims 4 to 9.